Details
Stereochemistry | ACHIRAL |
Molecular Formula | C29H33ClN2O3.H2O |
Molecular Weight | 511.052 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CN(C)C(=O)C(CC[N@+]1([O-])CC[C@](O)(CC1)C2=CC=C(Cl)C=C2)(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=MVMJRVIHTNVDRP-AYFKLSOTSA-N
InChI=1S/C29H33ClN2O3.H2O/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32(35)20-17-28(34,18-21-32)23-13-15-26(30)16-14-23;/h3-16,34H,17-22H2,1-2H3;1H2/t28-,32-;
Loperamide Oxide is a prodrug of loperamide, an antidiarrheal agent, patented by Belgian pharmaceutical company Janssen Pharmaceutica N. V. as an antidiarrheal agent. Loperamide oxide is reduced to loperamide and has the same antisecretory potency as loperamide in jejunum and colon. In clinical trials, Loperamide oxide provides a safe and effective treatment for chronic diarrhea associated with Crohn's disease. Loperamide Oxide is used in the Netherlands for the treatment of acute diarrhea in adults under brand name Arestal.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0055114 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7628301 |
PubMed
Title | Date | PubMed |
---|---|---|
Dose proportionality study of loperamide following oral administration of loperamide oxide. | 1992 |
|
Effects of the prodrug loperamide oxide, loperamide, and placebo on jejunal motor activity. | 1992 Feb |
|
Influence of loperamide and loperamide oxide on the anal sphincter. A manometric study. | 1992 Sep |
|
Loperamide oxide in the treatment of acute diarrhea in adults. | 1994 Nov-Dec |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8529776
1 or 2 mg after passage of each unformed stool for 1-week
The mean daily dose of loperamide oxide was 2.7 mg.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA07DA05
Created by
admin on Sat Dec 16 05:09:09 GMT 2023 , Edited by admin on Sat Dec 16 05:09:09 GMT 2023
|
||
|
WHO-ATC |
A07DA05
Created by
admin on Sat Dec 16 05:09:09 GMT 2023 , Edited by admin on Sat Dec 16 05:09:09 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB14661
Created by
admin on Sat Dec 16 05:09:09 GMT 2023 , Edited by admin on Sat Dec 16 05:09:09 GMT 2023
|
PRIMARY | |||
|
SUB23349
Created by
admin on Sat Dec 16 05:09:09 GMT 2023 , Edited by admin on Sat Dec 16 05:09:09 GMT 2023
|
PRIMARY | |||
|
100000087599
Created by
admin on Sat Dec 16 05:09:09 GMT 2023 , Edited by admin on Sat Dec 16 05:09:09 GMT 2023
|
PRIMARY | |||
|
H3VOT77DE1
Created by
admin on Sat Dec 16 05:09:09 GMT 2023 , Edited by admin on Sat Dec 16 05:09:09 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105114
Created by
admin on Sat Dec 16 05:09:09 GMT 2023 , Edited by admin on Sat Dec 16 05:09:09 GMT 2023
|
PRIMARY | |||
|
1600
Created by
admin on Sat Dec 16 05:09:09 GMT 2023 , Edited by admin on Sat Dec 16 05:09:09 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD